Biocorp
Biocorp designs and manufactures connected medical devices combining precision engineering with digital health sensor technology, including the FDA-cleared Mallya insulin pen sensor and SoloSmart connected drug delivery device. It supplies these as an OEM to pharmaceutical partners, operating as a wholly-owned subsidiary of Novo Nordisk following a 2023 acquisition.
- Company typePrivate
- Founded1997
- HeadquartersIssoire, France
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Biocorp does
Biocorp is a French medical device company that designs and manufactures connected drug delivery devices, combining precision plastics engineering with digital health sensor technology. The company was founded in 1997, is headquartered in Issoire, France, and operates two complementary sites: Clermont-Ferrand for development, innovation, and support functions, and Issoire for production and quality. The company employs approximately 105 people and is publicly listed under the ticker ALCOR on Euronext Paris, though it was acquired by Novo Nordisk in June 2023 for $178 million and now operates as a wholly-owned subsidiary within Novo Nordisk's digital health portfolio.
The company's product portfolio centers on two FDA-cleared connected devices. The Mallya insulin pen sensor is a smart connected sensor that attaches to insulin pens and received FDA approval in January 2023 for use with both insulin and GLP-1 receptor agonist pens. SoloSmart is a connected drug delivery device that received FDA 510(k) clearance in January 2024, extending the platform beyond diabetes-specific applications. The underlying technology integrates proprietary sensor hardware with connectivity for medication adherence tracking and remote monitoring, targeting the digital health and telehealth needs of chronic disease management.
Biocorp operates an OEM/embedded go-to-market model, supplying connected devices to pharmaceutical partners for integration into their drug delivery ecosystems. Revenue is generated through hardware sales of connected medical devices. Prior to the Novo Nordisk acquisition, the company served pharmaceutical companies in the diabetes care vertical as a B2B supplier. Post-acquisition, distribution is channeled through Novo Nordisk's global pharmaceutical network, positioning Biocorp's products within the diabetes franchise of one of the world's largest insulin and GLP-1 manufacturers. Pricing is not publicly disclosed and the customer base is narrow, with concentration risk in a small number of pharmaceutical OEM relationships.
Biocorp firmographics
Firmographics- Name
- Biocorp
- Legal name
- Biocorp
- Website
- https://biocorp.fr
- Company type
- Private
- Founded year
- 1997
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- Biocorp designs and manufactures connected medical devices combining precision engineering with digital health sensor technology, including the FDA-cleared Mallya insulin pen sensor and SoloSmart connected drug delivery device. It supplies these as an OEM to pharmaceutical partners, operating as a wholly-owned subsidiary of Novo Nordisk following a 2023 acquisition.
- Ownership category
- akta.pro rank
Biocorp industry classification
Industry- Product category
- Connected Medical Devices
- NAICS
- Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Drug Delivery Connectivity, Sensors & Digital Add-Ons (Smart Caps/Companion Apps) (HLAHAIAM)
- akta.pro secondary industries
- Smart Insulin Pens & Connected Pen Caps (HLAHAHAD), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)
Keywords
Where Biocorp is headquartered
LocationHeadquarters
- HQ city
- Issoire
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
Biocorp business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Connected Medical Device Manufacturing: Design and manufacture of connected medical devices, operating as a wholly-owned subsidiary of Novo Nordisk following the June 2023 acquisition
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Biocorp product offering
Product offeringCore offering
Biocorp designs and manufactures connected medical devices that combine precision plastics engineering with digital health technologies, including the Mallya smart insulin pen sensor (FDA-approved January 2023) and the SoloSmart connected drug delivery device (FDA 510(k) cleared January 2024). The company supplies these devices to pharmaceutical partners on an OEM/embedded basis for integration into their drug delivery ecosystems, with end-to-end capabilities spanning R&D, manufacturing, and final packaging across its Clermont-Ferrand and Issoire sites in France.
Product overview
Biocorp designs and manufactures connected medical devices combining precision engineering with digital health technologies. The company operates two product lines: the Mallya Insulin Pen Sensor (FDA-approved smart sensor for insulin/GLP-1 pens) and SoloSmart (FDA 510(k)-cleared connected drug delivery device). Biocorp employs 105 people across two sites in France (Clermont-Ferrand for development/innovation and Issoire for manufacturing/quality), offering end-to-end capabilities from R&D through final packaging.
Differentiator
Problem solved
Functional benefit
Brands
- Mallya: Smart connected insulin pen sensor for diabetes management
- SoloSmart
Products and services
- Mallya Insulin Pen Sensor A smart connected device sensor that attaches to insulin pens, providing digital health monitoring and data tracking for diabetes management. Received FDA approval in January 2023 for use with insulin and GLP-1 receptor agonist pens. Targeted at pharmaceutical partners for integration with their diabetes therapy delivery systems.
- SoloSmart A connected drug delivery device that received FDA 510(k) clearance in January 2024, designed to enhance medication adherence and enable remote patient monitoring through digital connectivity. Targeted at pharmaceutical partners for chronic disease management applications.
Quantifiable outcome
- Mallya insulin pen sensor received FDA approval for use with insulin and GLP-1 receptor agonist pens
Companies that use Biocorp
Customer profileSegments1 record
Ideal customer profiles1 record
Biocorp technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Biocorp partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights5 records
Biocorp competitors and assessment
Company assessmentEmerging players
- Bigfoot Biomedical: US-based emerging player developing smart pen caps and connected insulin delivery systems, with a similar product architecture and target use case to Biocorp's Mallya though at earlier commercial scale.
Broad incumbents
- Dexcom: Leader in continuous glucose monitoring (CGM) hardware, complementary to Biocorp's Mallya. As CGM expands, Dexcom's data platform overlaps with the connected diabetes ecosystem Biocorp serves, creating both partnership and competitive overlap.
- Tandem Diabetes Care: US-based connected insulin pump manufacturer (t:slim X2) integrated with CGM and increasingly focused on automated insulin delivery. A broader diabetes device incumbent that addresses the same patient population as Biocorp's connected pen sensors.
- Medtronic Diabetes: Major medical device incumbent with an integrated portfolio spanning insulin pumps, CGM, and smart insulin pen connectivity. Competes with Biocorp in the broader connected diabetes care ecosystem and has substantially greater R&D and commercial resources.
- Sanofi Diabetes: Global pharmaceutical company with a major diabetes franchise and prior experience with connected insulin pen initiatives (e.g., partnership with BioCorp's ecosystem). A potential large customer/competitor to Biocorp's smart pen sensor business.
- Abbott Diabetes Care: Operates the FreeStyle Libre CGM franchise and broader diabetes care portfolio. A large incumbent with overlapping digital health data ambitions relevant to Biocorp's connected injectable therapy positioning.
- Insulet Corporation: US-based leader in tubeless insulin pump technology (Omnipod). A broader incumbent in connected insulin delivery that competes for the same pharmaceutical and patient mindshare as Biocorp's smart pen sensor products.
- Roche Diabetes Care: Operates the Accu-Chek franchise of blood glucose monitors, insulin pumps, and digital diabetes management tools. A broad incumbent with overlapping interest in connected injectable therapy adherence and remote monitoring.
Direct peers
- Ypsomed: Swiss medical device company and one of the closest direct competitors to Biocorp, offering YpsoMate and the SmartPilot/YpsoPod connected pen solutions for insulin and GLP-1 injectable delivery. Both companies supply OEM-style smart sensor add-ons to pharmaceutical partners.
- Emperra GmbH: German developer of the Esysta smart insulin pen and connected diabetes management system, directly comparable to Biocorp's Mallya in both technology (pen-attached smart sensor) and customer base (pharmaceutical partners, diabetes patients).
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks4 records
Key highlights5 records
Customer concentration
Biocorp social profiles
Digital presenceBiocorp compliance and trust
Trust signalCompliance2 records
Biocorp financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biocorp leadership team
Management profileNumber of profiles
Profiles1 record
Biocorp funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biocorp M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biocorp
What does Biocorp do?
Biocorp designs and manufactures connected medical devices that combine precision plastics engineering with digital health technologies, including the Mallya smart insulin pen sensor (FDA-approved January 2023) and the SoloSmart connected drug delivery device (FDA 510(k) cleared January 2024). The company supplies these devices to pharmaceutical partners on an OEM/embedded basis for integration into their drug delivery ecosystems, with end-to-end capabilities spanning R&D, manufacturing, and final packaging across its Clermont-Ferrand and Issoire sites in France.
Is Biocorp a public or private company?
Biocorp is a private company. It is classified as corporate owned and is currently acquired.
When was Biocorp founded?
Biocorp was founded in 1997. It employs 51 to 100 people.
Where is Biocorp based?
Biocorp is headquartered in Issoire, France, in the Europe region.
How does Biocorp make money?
One revenue line is on record: connected Medical Device Manufacturing.
Who are Biocorp's main competitors?
Bigfoot Biomedical is listed as an emerging player. Broad incumbents are Dexcom, Tandem Diabetes Care, Medtronic Diabetes, Sanofi Diabetes, Abbott Diabetes Care, Insulet Corporation and Roche Diabetes Care. Direct peers are Ypsomed and Emperra GmbH.
Does Biocorp have an API?
No public API is recorded for Biocorp.
What industry is Biocorp in?
Biocorp's product category is Connected Medical Devices. Its primary akta.pro industry code is HLAHAIAM, Drug Delivery Connectivity, Sensors & Digital Add-Ons (Smart Caps/Companion Apps), with a secondary code of HLAHAHAD, Smart Insulin Pens & Connected Pen Caps. Its NAICS code is 3345 and its SIC code is 3845.